PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.07%
Negative revenue growth while CVE stands at 8.70%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-15.51%
Negative gross profit growth while CVE is at 5.66%. Joel Greenblatt would examine cost competitiveness or demand decline.
-37.21%
Negative EBIT growth while CVE is at 19.34%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-37.21%
Negative operating income growth while CVE is at 19.34%. Joel Greenblatt would press for urgent turnaround measures.
133.62%
Net income growth at 75-90% of CVE's 148.99%. Bill Ackman would press for improvements to catch or surpass competitor performance.
131.25%
EPS growth similar to CVE's 145.45%. Walter Schloss would assume both have parallel share structures and profit trends.
131.25%
Similar diluted EPS growth to CVE's 145.45%. Walter Schloss might see standard sector or cyclical influences on both firms.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.96%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-18.66%
Negative OCF growth while CVE is at 142.67%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-52.08%
Negative FCF growth while CVE is at 212.10%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-27.47%
Negative 10Y revenue/share CAGR while CVE stands at 92.15%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-57.22%
Negative 5Y CAGR while CVE stands at 92.15%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-20.55%
Negative 3Y CAGR while CVE stands at 35.60%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
19.51%
10Y OCF/share CAGR at 50-75% of CVE's 38.76%. Martin Whitman might fear a structural deficiency in operational efficiency.
-60.24%
Negative 5Y OCF/share CAGR while CVE is at 38.76%. Joel Greenblatt would question the firm’s operational model or cost structure.
-20.86%
Negative 3Y OCF/share CAGR while CVE stands at 43.68%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
34.57%
Below 50% of CVE's 281.38%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
14.92%
Below 50% of CVE's 281.38%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
53.00%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-25.90%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-71.54%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-60.18%
Negative 3Y equity/share growth while CVE is at 17.65%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
34.87%
Dividend/share CAGR of 34.87% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-83.16%
Negative 5Y dividend/share CAGR while CVE stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-66.20%
Negative near-term dividend growth while CVE invests at 32.62%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-3.69%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-4.28%
Inventory is declining while CVE stands at 3.13%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
8.90%
Asset growth above 1.5x CVE's 0.54%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
32.38%
BV/share growth above 1.5x CVE's 3.19%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-1.51%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
3.53%
We expand SG&A while CVE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.